RE: Chronic cure?This a cure for generally the severe version, therefore at this moment its kind of lets worry about side affects later. Recently given "unusually effective" title by the FDA, it would give the company as idealistic boost. Now the rest of the income would come how well they can market the drug (which is a huge issue in the biotech world) because not always an effective drug will sell. Do they have the income to market? Also it would depend on how much their partners get out of this.